Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07661979
PHASE4

Opzelura Experience Study

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.

Key Details

Gender

All

Age Range

2 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2026-08

Completion Date

2027-10

Last Updated

2026-07-14

Healthy Volunteers

No

Interventions

DRUG

ruxolitinib

patients are directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed

DRUG

ruxolitinib and an Eczema Action Plan

patients will be directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed. Patients will also be provided an Eczema Action Plan (EAP) with recommended lifestyle recommendations, including what cleanser to use, allergen avoidance, use of moisturizers, and bathing practices as determined by disease severity

Locations (1)

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States